Education
About Us
Working with TipRanks
Follow Us
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
Total Valuation
Inhibikase Therapeutics has a market cap or net worth of $123.41M. The enterprise value is $5.77M.
Market Cap$123.41M
Enterprise Value$5.77M
Share Statistics
Inhibikase Therapeutics has 74,341,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding74,341,540
Owned by Insiders9.83%
Owned by Institutions60.86%
Financial Efficiency
Inhibikase Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -30.10%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-30.10%
Return on Capital Employed (ROCE)-0.30
Revenue Per Employee0.00
Profits Per Employee-1.83M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Inhibikase Therapeutics is -2.80. Inhibikase Therapeutics’s PEG ratio is 0.06.
PE Ratio-2.80
PS Ratio0.00
PB Ratio0.60
Price to Fair Value0.81
Price to FCF-0.72
Price to Operating Cash Flow-0.73
PEG Ratio0.06
Income Statement
In the last 12 months, Inhibikase Therapeutics had revenue of 0.00 and earned -27.52M in profits. Earnings per share was -1.16.
Revenue0.00
Gross Profit0.00
Operating Income-28.59M
Pretax Income-27.52M
Net Income-27.52M
EBITDA-27.49M
Earnings Per Share (EPS)-1.16
Cash Flow
In the last 12 months, operating cash flow was -19.38M and capital expenditures 0.00, giving a free cash flow of -19.38M billion.
Operating Cash Flow-19.38M
Free Cash Flow-19.38M
Free Cash Flow per Share-0.26
Dividends & Yields
Inhibikase Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.78
52-Week Price Change24.81%
50-Day Moving Average1.99
200-Day Moving Average2.23
Relative Strength Index (RSI)35.36
Average Volume (3m)124.92K
Important Dates
Inhibikase Therapeutics upcoming earnings date is Aug 18, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
Inhibikase Therapeutics as a current ratio of 26.37, with Debt / Equity ratio of 1.67%
Current Ratio26.37
Quick Ratio26.37
Debt to Market Cap<0.01
Net Debt to EBITDA2.05
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Inhibikase Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Inhibikase Therapeutics EV to EBITDA ratio is -0.75, with an EV/FCF ratio of -1.08.
EV to Sales0.00
EV to EBITDA-0.75
EV to Free Cash Flow-1.08
EV to Operating Cash Flow-1.08
Balance Sheet
Inhibikase Therapeutics has $93.18M in cash and marketable securities with $74.77K in debt, giving a net cash position of -$93.11M billion.
Cash & Marketable Securities$93.18M
Total Debt$74.77K
Net Cash-$93.11M
Net Cash Per Share-$1.25
Tangible Book Value Per Share$4.00
Margins
Gross margin is 94.55%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin94.55%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Inhibikase Therapeutics is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.00
Price Target Upside381.93% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-100.00%
EPS Growth Forecast38.72%